Ono Pharmaceutical Co., Ltd.

Ono Pharmaceuticals Co., Ltd.

Shingo Nakatani

Takashi Morimoto

Tetsuya Sugiyama

Akira Ohata

Takashi Kondo

Ryo Suzuki

Hisao Nakai

Shingo Yamamoto

Gareth Neil Brace

Sho Kouyama

Stuart Flanagan

Osamu Ichihara

Chris Yarnold

Steve Courtney

Akira Imagawa

Elise Gadouleau

John Barker

Tomomi Hirosaki

Anthony Richardson

Barker John

Gareth Brace

The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases. 

Pyrimidinone and its derivatives inhibiting factor XIa

An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.

Tetrahydrocarboline derivative

Pyridinone and pyrimidinone derivatives as factor Xia

It is intended to provide a compound represented by the formula (I): 

Nitrogen-containing heterocyclic compound and pharmaceutical application thereof

The present invention relates to a compound that has p38 MAP kinase inhibitory activity useful as drug medicine, represented by the general formula (I):  The compound of the general formula (I) has a p38 MAP kinase inhibitory activity and is useful for the prevention and/or treatment of diseases in which an abnormal production of cytokine, such as inflammatory cytokine or chemokine, or an over-reaction thereto would be instrumental in the cause and aggravation of pathologic condition thereof, namely, cytokine-mediated diseases, for example, inflammatory diseases, respiratory diseases, circulatory diseases, central nervous diseases, etc.

Nitrogenous heterocyclic compound and pharmaceutical use thereof

Growing community of inventors

Osaka, Japan

Shingo Nakatani